Skip to main content
Top
Published in: BMC Clinical Pathology 1/2014

Open Access 01-12-2014 | Research article

The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk

Authors: Thomas K Kilvaer, Eivind Smeland, Andrej Valkov, Sveinung W Sorbye, Roy M Bremnes, Lill-Tove Busund, Tom Donnem

Published in: BMC Clinical Pathology | Issue 1/2014

Login to get access

Abstract

Background

Soft-tissue sarcomas are rare malignant tumors of mesenchymal lineage that can arise in any part of the body. Prognosis, and hence also treatment may vary according to histologic subtype and localization. Angiogenesis is the process of forming new blood vessels from pre-existing ones. The deregulation of this process is thought to be an important step in malignant transformation. This study investigates the prognostic impact of platelet derived growth factor- (PDGF), vascular endothelial growth factor- (VEGF) and fibroblast growth factor (FGF) families in soft-tissue sarcomas of the extremities & trunk (ET) and visceral & retroperitoneal (VR) locations.

Methods

Tumor samples from 181 patients (115 ET and 66 VR) with resected soft tissue sarcomas were collected and tissue microarrays were constructed. Immunohistochemistry was used to evaluate angiogenic marker expression. Recurrence-free survival (RFS), metastasis-free survival (MFS) and disease-specific survival (DSS) were used as endpoints in prognostic impact assessment.

Results

In univariate analyses, almost all investigated angiogenic markers had prognostic impact in the ET group. In contrast, only FGFR-1 showed any significant prognostic impact in the VR group. In the multivariate analyses, PDGF-D (HR = 1.863, 95% CI = 1.057-3.283, P = 0.031), VEGFR-1 (HR = 2.106, 95% CI = 1.038-4.272, P = 0.039) and VEGF-A (HR 2.095, 95% CI 1.028-4.271, P = 0.042) were independent negative prognosticators for DSS, MFS and RFS, respectively, in the ET group. FGFR-1 was an independent positive prognosticator for DSS (HR = 0.243, 95% CI = 0.095-0.618, P = 0.003) in the VR group.

Conclusions

Angiogenic molecules from the PDGF and VEGF families have prognostic impact in soft-tissue sarcomas arising in the ET, but not in VR locations. In the latter histological grade and resection margins are the most important prognostic factors.
Literature
1.
go back to reference Fletcher CDM, Unni KK, Mertens F: Pathology and genetics of tumours of soft tissue and bone. World Health Organization Classification of Tumours. 2002, Lyon: IARC Press, 415- Fletcher CDM, Unni KK, Mertens F: Pathology and genetics of tumours of soft tissue and bone. World Health Organization Classification of Tumours. 2002, Lyon: IARC Press, 415-
2.
go back to reference Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62 (1): 10-29. 10.3322/caac.20138.CrossRefPubMed Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62 (1): 10-29. 10.3322/caac.20138.CrossRefPubMed
3.
go back to reference Group E.E.S.N.W: Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012, 23 (Suppl 7): vii92-vii99. Group E.E.S.N.W: Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012, 23 (Suppl 7): vii92-vii99.
4.
go back to reference Dickinson IC, et al: Surgical margin and its influence on survival in soft tissue sarcoma. ANZ J Surg. 2006, 76 (3): 104-109. 10.1111/j.1445-2197.2006.03615.x.CrossRefPubMed Dickinson IC, et al: Surgical margin and its influence on survival in soft tissue sarcoma. ANZ J Surg. 2006, 76 (3): 104-109. 10.1111/j.1445-2197.2006.03615.x.CrossRefPubMed
5.
go back to reference Blay JY, Le Cesne A: Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven. Oncologist. 2009, 14 (10): 1013-1020. 10.1634/theoncologist.2009-0126.CrossRefPubMed Blay JY, Le Cesne A: Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven. Oncologist. 2009, 14 (10): 1013-1020. 10.1634/theoncologist.2009-0126.CrossRefPubMed
8.
go back to reference Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100 (1): 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100 (1): 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
9.
go back to reference Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144 (5): 646-674. 10.1016/j.cell.2011.02.013.CrossRefPubMed Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144 (5): 646-674. 10.1016/j.cell.2011.02.013.CrossRefPubMed
10.
go back to reference Tammela T, et al: The biology of vascular endothelial growth factors. Cardiovasc Res. 2005, 65 (3): 550-563. 10.1016/j.cardiores.2004.12.002.CrossRefPubMed Tammela T, et al: The biology of vascular endothelial growth factors. Cardiovasc Res. 2005, 65 (3): 550-563. 10.1016/j.cardiores.2004.12.002.CrossRefPubMed
11.
go back to reference Fredriksson L, Li H, Eriksson U: The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004, 15 (4): 197-204. 10.1016/j.cytogfr.2004.03.007.CrossRefPubMed Fredriksson L, Li H, Eriksson U: The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004, 15 (4): 197-204. 10.1016/j.cytogfr.2004.03.007.CrossRefPubMed
12.
go back to reference Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 2004, 15 (4): 275-286. 10.1016/j.cytogfr.2004.03.002.CrossRefPubMed Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 2004, 15 (4): 275-286. 10.1016/j.cytogfr.2004.03.002.CrossRefPubMed
13.
go back to reference Presta M, et al: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005, 16 (2): 159-178. 10.1016/j.cytogfr.2005.01.004.CrossRefPubMed Presta M, et al: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005, 16 (2): 159-178. 10.1016/j.cytogfr.2005.01.004.CrossRefPubMed
14.
go back to reference Kilvaer TK, et al: Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. J Transl Med. 2011, 9: 104-10.1186/1479-5876-9-104.CrossRefPubMedPubMedCentral Kilvaer TK, et al: Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. J Transl Med. 2011, 9: 104-10.1186/1479-5876-9-104.CrossRefPubMedPubMedCentral
15.
go back to reference Kilvaer TK, et al: Platelet-derived growth factors in non-GIST soft-tissue sarcomas identify a subgroup of patients with wide resection margins and poor disease-specific survival. Sarcoma. 2010, 2010: 751304-CrossRefPubMed Kilvaer TK, et al: Platelet-derived growth factors in non-GIST soft-tissue sarcomas identify a subgroup of patients with wide resection margins and poor disease-specific survival. Sarcoma. 2010, 2010: 751304-CrossRefPubMed
16.
go back to reference Kilvaer TK, et al: Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS One. 2010, 5 (12): e15368-10.1371/journal.pone.0015368.CrossRefPubMedPubMedCentral Kilvaer TK, et al: Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS One. 2010, 5 (12): e15368-10.1371/journal.pone.0015368.CrossRefPubMedPubMedCentral
17.
go back to reference Guillou L, et al: Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997, 15 (1): 350-362.PubMed Guillou L, et al: Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997, 15 (1): 350-362.PubMed
18.
go back to reference Yudoh K, et al: Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer. 2001, 84 (12): 1610-1615. 10.1054/bjoc.2001.1837.CrossRefPubMedPubMedCentral Yudoh K, et al: Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer. 2001, 84 (12): 1610-1615. 10.1054/bjoc.2001.1837.CrossRefPubMedPubMedCentral
19.
go back to reference Tallquist M, Kazlauskas A: PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004, 15 (4): 205-213. 10.1016/j.cytogfr.2004.03.003.CrossRefPubMed Tallquist M, Kazlauskas A: PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004, 15 (4): 205-213. 10.1016/j.cytogfr.2004.03.003.CrossRefPubMed
20.
go back to reference Li H, et al: PDGF-D is a potent transforming and angiogenic growth factor. Oncogene. 2003, 22 (10): 1501-1510. 10.1038/sj.onc.1206223.CrossRefPubMed Li H, et al: PDGF-D is a potent transforming and angiogenic growth factor. Oncogene. 2003, 22 (10): 1501-1510. 10.1038/sj.onc.1206223.CrossRefPubMed
21.
go back to reference Chao C, et al: Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol. 2001, 8 (3): 260-267. 10.1007/s10434-001-0260-9.CrossRefPubMed Chao C, et al: Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol. 2001, 8 (3): 260-267. 10.1007/s10434-001-0260-9.CrossRefPubMed
22.
go back to reference Graeven U, et al: Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol. 1999, 125 (10): 577-581. 10.1007/s004320050319.CrossRefPubMed Graeven U, et al: Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol. 1999, 125 (10): 577-581. 10.1007/s004320050319.CrossRefPubMed
23.
go back to reference Hayes AJ, et al: Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg. 2004, 91 (2): 242-247. 10.1002/bjs.4398.CrossRefPubMed Hayes AJ, et al: Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg. 2004, 91 (2): 242-247. 10.1002/bjs.4398.CrossRefPubMed
24.
go back to reference Yoon SS, et al: Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol. 2004, 15 (8): 1261-1266. 10.1093/annonc/mdh309.CrossRefPubMed Yoon SS, et al: Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol. 2004, 15 (8): 1261-1266. 10.1093/annonc/mdh309.CrossRefPubMed
25.
go back to reference Yoon SS, et al: Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res. 2006, 135 (2): 282-290. 10.1016/j.jss.2006.01.023.CrossRefPubMed Yoon SS, et al: Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res. 2006, 135 (2): 282-290. 10.1016/j.jss.2006.01.023.CrossRefPubMed
26.
go back to reference Adams RH, Alitalo K: Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007, 8 (6): 464-478. 10.1038/nrm2183.CrossRefPubMed Adams RH, Alitalo K: Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007, 8 (6): 464-478. 10.1038/nrm2183.CrossRefPubMed
27.
go back to reference Hiratsuka S, et al: MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2002, 2 (4): 289-300. 10.1016/S1535-6108(02)00153-8.CrossRefPubMed Hiratsuka S, et al: MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2002, 2 (4): 289-300. 10.1016/S1535-6108(02)00153-8.CrossRefPubMed
28.
go back to reference Kaplan RN, et al: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005, 438 (7069): 820-827. 10.1038/nature04186.CrossRefPubMedPubMedCentral Kaplan RN, et al: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005, 438 (7069): 820-827. 10.1038/nature04186.CrossRefPubMedPubMedCentral
29.
go back to reference Lorusso PM, et al: Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2013, 1-9. Lorusso PM, et al: Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2013, 1-9.
31.
go back to reference Welti JC, et al: Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene. 2011, 30 (10): 1183-1193. 10.1038/onc.2010.503.CrossRefPubMed Welti JC, et al: Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene. 2011, 30 (10): 1183-1193. 10.1038/onc.2010.503.CrossRefPubMed
32.
go back to reference Ohshima M, et al: bFGF rescues imatinib/STI571-induced apoptosis of sis-NIH3T3 fibroblasts. Biochem Biophys Res Commun. 2009, 381 (2): 165-170. 10.1016/j.bbrc.2009.02.012.CrossRefPubMed Ohshima M, et al: bFGF rescues imatinib/STI571-induced apoptosis of sis-NIH3T3 fibroblasts. Biochem Biophys Res Commun. 2009, 381 (2): 165-170. 10.1016/j.bbrc.2009.02.012.CrossRefPubMed
Metadata
Title
The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk
Authors
Thomas K Kilvaer
Eivind Smeland
Andrej Valkov
Sveinung W Sorbye
Roy M Bremnes
Lill-Tove Busund
Tom Donnem
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Clinical Pathology / Issue 1/2014
Electronic ISSN: 1472-6890
DOI
https://doi.org/10.1186/1472-6890-14-5

Other articles of this Issue 1/2014

BMC Clinical Pathology 1/2014 Go to the issue